ImmunityBio Inc. [NASDAQ: IBRX] traded at a high on 09/14/22, posting a 13.65 gain after which it closed the day’ session at $6.41. The company report on July 28, 2022 that ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ.
Top 5 Tech Stocks Every Investor Should Buy Right Now
While finding excellent stocks with the potential for gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Tech Stocks Every Investor Should Buy Right Now", we have identified five tech stocks we believe could appreciate.
Sign up here to get your free report now.
This acceptance represents the first regulatory filing for N-803, an IL-15 superagonist, which was granted Breakthrough Therapy and Fast Track designations in combination with Bacillus Calmette-Guérin (BCG) from the U.S. Food and Drug Administration (FDA) for this indication with a target PDUFA date of May 23, 2023.
The BLA submission is based on the positive QUILT 3.032 trial results in which 71% of BCG-unresponsive NMIBC patients who had failed on previous therapies showed a complete response with a median duration of 26.6 months; cystectomy avoidance rate of 91% and 100% bladder cancer overall survival at 24 months with zero serious adverse events (SAE).
The results of the trading session contributed to over 3795987 shares changing hands. Over the past one week, the price volatility of ImmunityBio Inc. stands at 12.77% while the volatility over the past one month is 8.97%.
The market cap for IBRX stock reached $2.12 billion, with 397.99 million shares outstanding and 83.44 million shares in the current float. Compared to the average trading volume of 1.50M shares, IBRX reached a trading volume of 3795987 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about ImmunityBio Inc. [IBRX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBRX shares is $9.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for ImmunityBio Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 03, 2022.
The Average True Range (ATR) for ImmunityBio Inc. is set at 0.43, with the Price to Sales ratio for IBRX stock in the period of the last 12 months amounting to 4244.57.
How has IBRX stock performed recently?
ImmunityBio Inc. [IBRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 42.13. With this latest performance, IBRX shares gained by 35.52% in over the last four-week period, additionally plugging by 19.37% over the last 6 months – not to mention a drop of -31.37% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBRX stock in for the last two-week period is set at 76.87, with the RSI for the last a single of trading hit 84.42, and the three-weeks RSI is set at 71.02 for ImmunityBio Inc. [IBRX]. The present Moving Average for the last 50 days of trading for this stock 4.40, while it was recorded at 5.41 for the last single week of trading, and 5.04 for the last 200 days.
ImmunityBio Inc. [IBRX]: Deeper insight into the fundamentals
ImmunityBio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.30 and a Current Ratio set at 0.30.
Earnings analysis for ImmunityBio Inc. [IBRX]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IBRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ImmunityBio Inc. go to -1.70%.
Insider trade positions for ImmunityBio Inc. [IBRX]
There are presently around $213 million, or 8.70% of IBRX stock, in the hands of institutional investors. The top three institutional holders of IBRX stocks are: VANGUARD GROUP INC with ownership of 7,522,377, which is approximately 5.118% of the company’s market cap and around 79.61% of the total institutional ownership; BLACKROCK INC., holding 5,907,649 shares of the stock with an approximate value of $37.87 million in IBRX stocks shares; and STATE STREET CORP, currently with $11.98 million in IBRX stock with ownership of nearly -72.36% of the company’s market capitalization.
Positions in ImmunityBio Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 75 institutional holders increased their position in ImmunityBio Inc. [NASDAQ:IBRX] by around 5,232,541 shares. Additionally, 64 investors decreased positions by around 7,629,528 shares, while 28 investors held positions by with 20,333,687 shares. The mentioned changes placed institutional holdings at 33,195,756 shares, according to the latest SEC report filing. IBRX stock had 20 new institutional investments in for a total of 1,002,706 shares, while 30 institutional investors sold positions of 1,125,384 shares during the same period.